XAIR241220C7500
- 0.00
- 0.000.00%
Beyond Air Newsroom
National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for Its INO Products
Express News | Beyond Cancer: Israeli Ministry of Health Approved Use of Low Volume Uno in Phase 1B Clinical Trial of Lv Uno in Combination With Anti-Pd-1 Therapy
Express News | Advisory- Alert on Beyond Cancer's Clinical Trial Approval Was Incorrectly Tagged to Beyond Air and Is Being Withdrawn
Beyond Air Announces IMOH Approval of LV UNO Trial
Beyond Cancer Secures Approval From Israeli Ministry Of Health For Phase 1b Trial Combining Low Volume Ultra-High Concentration Nitric Oxide With Anti-PD-1 Therapy In Solid Tumor Patients
Express News | Beyond Air Receives Ce Mark in Europe for the Lungfit® Ph System
Beyond Air Approves Key Changes at Annual Meeting
Beyond Air's NeuroNOS Appoints Kornberg to SAB
Express News | Neuronos Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
Press Release: NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
Beyond Air | 8-K: Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
Beyond Air Faces Nasdaq Delisting Threat: Stock Price and Liquidity at Risk
Beyond Air Reports Increased Revenue Amid Financial Challenges
Beyond Air | 10-Q: Q2 2025 Earnings Report
BTIG Maintains Beyond Air(XAIR.US) With Hold Rating
Piper Sandler Maintains Beyond Air(XAIR.US) With Buy Rating, Maintains Target Price $1
Ladenburg Thalmann Maintains Beyond Air(XAIR.US) With Buy Rating, Cuts Target Price to $2
Piper Sandler Releases a Buy Rating on Beyond Air (XAIR)
Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript Summary